We retrospectively evaluated the incidence and time from transplantation of bloodstream infections occurring in children receiving bone marrow transplant (BMT) at G Gaslini Children's Hospital between September 1984 and December 1997. During this period the incidence was 35% after allogeneic and 26% after autologous BMT (P = 0.08). Among these episodes, 38% after allogeneic BMT and 90% after autologous BMT were detected in the presence of neutropenia within the first 30 days from reinfusion (P Ͻ Ͻ Ͻ 0.001). Incidence of catheter-related bloodstream infections was 40% after allogeneic and 8% after autologous BMT (P Ͻ Ͻ Ͻ 0.001). Bloodstream infections in the absence of neutropenia were 55% after allogeneic BMT vs 10% after autologous BMT (P Ͻ Ͻ Ͻ 0.001) and occurred later after reinfusion (mean 199 vs 41 days, P Ͻ Ͻ0.001). Among the episodes occurring after allogeneic BMT and in the absence of neutropenia, 61% were related to the presence of a central venous catheter, 15% were related to the presence of GVHD, but 23% were not associated with any of major risk factors for infection. Finally, 38% of episodes following allogeneic BMT were detected after day 100 vs 1% after autologous BMT. We concluded that patients receiving allogeneic BMT experience a high incidence of bloodstream infections in the absence of neutropenia and that a significant proportion of these episodes is not clearly associated with well known risk factors such as GVHD or central venous catheters. Moreover, many episodes develop a long time after the transplantation procedure. Therefore, any febrile episode following allogeneic BMT even late and/or in the absence of neutropenia should be intensively managed. Keywords: bacteremia; children; marrow transplant; late infections
of the presence of many quantitative and qualitative defects in anti-infective mechanisms.
1,2 Some of these defects, such as mucosistis and bone marrow aplasia, are strictly related to conditioning therapy preceding BMT, while others, observed after allogeneic BMT are generally related to the presence of graft-versus host disease (GVHD) and its prophylaxis or treatment. Finally, mechanical defects due to the presence of indwelling central venous catheters (CVC) are present through the whole treatment period and generally for long durations.
1,2 All these mechanisms, and probably many others, produce their greatest influence generally within the first 3 months after transplantation, and many studies have noted the high incidence and severity of bacterial and fungal infections which are often life-threatening, within day 100 from transplantation. 1, 3, 4 Nevertheless, patients receiving bone marrow transplants (especially from matched-unrelated donors) are not free of life-threatening risk of infection even after 3 months from transplantation. 1, [3] [4] [5] [6] We retrospectively examined our experience in children undergoing bone marrow transplantation and evaluated bloodstream infections (BI) occurring in children after BMT procedures, the time from transplantation when episodes occurred, presence of predisposing factors, such as neutropenia and GVHD, and the relationship of BI with the presence of CVC. Data were then compared with those obtained from patients undergoing autologous BMT.
Patients and methods

Patient population and study period
All clinical records of children undergoing BMT procedures in the period September 1984 to December 1997 at the Bone Marrow Transplantation Unit of G Gaslini Children's Hospital, Genova, Italy were retrospectively reviewed.
For each patient the following data were recorded: type of BMT, etiology of BI, presence of granulocytopenia (absolute neutrophil count Ͻ1000/mm 3 ) at time of diagnosis of BI, relationship of the episode with CVC and presence of acute or chronic GVHD at time of diagnosis of infection. Moreover, date of BMT and date of BI were also recorded in order to calculate the time-to-infection in the period following BMT. The period of observation after BMT was interrupted in the case of death or relapse of the underlying disease, and in surviving patients it was censored at 31/12/1997.
Diagnosis of bloodstream infection
Single agent BI was defined as the isolation of a single pathogen (bacterial or fungal) from blood culture. For coagulase-negative staphylococci, corynebacteria other than Corynebacterium jeikeium, and other skin contaminants, at least two sets of positive blood cultures were required, unless the same pathogen was concomitantly isolated from blood and another site of infection. Mixed/polymicrobal BI was defined as isolation of more than one pathogen from the same blood sample or from two consecutive samples obtained within 24 h. A febrile illness occurring with isolation of fungal organisms in one or more blood cultures, without evidence of visceral involvement was defined as isolated fungal BI.
The infection was defined as CVC related in the presence of: (1) fever (Ͼ38°C) with chills and rigors after catheter flushing or manipulation and/or (2) isolation of a pathogen only from blood drawn through the CVC, but not from phlebotomy; (3) isolation of the same pathogen from the CVC tip (after removal) and blood cultures; (4) isolation of the same organism from blood cultures and from purulent material draining from the catheter exit site or subcutaneous tunnel. In all the remaining cases, sepsis was defined as non-catheter related. 7 
Statistical analysis
For continuous variables, mean values and 95% confidence interval (95% CI) were calculated and differences were evaluated by means of the t-test for independent variables. Differences among categorical variables were evaluated by means of the 2 test for heterogeneity or for trend, or Fisher's exact test, when applicable. Statistical significance was considered P = 0.05. All tests were two-tailed.
Results
Among the 442 BMT procedures, 129 (29%) BIs were documented. Single agent bacterial infections were predominant, accounting for a total of 117 (86%) events: 90 (70%) episodes were due to Gram-positive bacteria and 27 (21%) to Gram-negatives. Mixed-polymicrobial infections were documented in nine (7%) of cases and fungal infections in three (2%) of cases.
A total of 95 (74%) episodes occurred in the presence of neutropenia. Of these, 70 (74%) were due to Gram-positive bacteria, 17 (18%) to Gram-negatives, six (6%) to mixed/polymicrobial, and two (2%) to fungi. In the absence of neutropenia 34 (26%) episodes were documented; of these, 20 (59%) were caused by Gram-positive bacteria, 10 (29%) by Gram-negatives, three (9%) were due to mixed/polymicrobial, and one (3%) to fungi.
A CVC was present during all BMT procedures. CVCrelated infections accounted for a total of 26 events: 6% of all CVC. CVC-related BI represented 20% of all documented episodes. Among CVC-related BIs, 21 (80%) occurred in the absence of neutropenia and only five during neutropenia: of all, 14 episodes were due to Gram-positive bacteria, six to Gram-negative, two to fungi and four were mixed/polymicrobial.
Episodes observed during allogeneic BMT procedures
Among the 442 BMT procedures, 133 (30%) were allogeneic BMT. During a follow-up of 28 131 days (mean 740, 95% CI 453-1028), 47 episodes of BI were diagnosed, with a rate of 0.17 episode/100 days at risk.
Among the 47 episodes, 21 (45%) were observed in the presence of neutropenia after a mean of 35 days (95% CI 10-61) from transplantation. Gram-positives were responsible for 12 (57%) episodes, six (28.5%) were due to Gramnegatives, one (4.7%) to fungi, and two (9.5%) were mixed/polymicrobial. The 26 (55%) remaining events occurred in the absence of neutropenia, after a mean of 199 days (95% CI 118-280) from transplantation, and were caused by Gram-positives in 14 (53.8%) cases, by Gramnegatives in eight (30.7%), by fungi in one (3.8%), while three (11.5%) were mixed/polymicrobial.
There were 19 CVC-related episodes (14% of CVC) which represented 40% of BIs in allogeneic BMT recipients. Among these episodes, eight (42%) were due to Gram-positives, five (26.3%) to Gram-negatives, two (10.5%) to fungi and four (21%) were mixed/ polymicrobial. Table 1 shows the etiology of BIs according to the presence or absence of neutropenia. Table 2 shows the etiology of CVC-related and non-related BIs, stratified according to the type of BMT procedure.
GVHD was present in 12 (25%) of the episodes at the time of diagnosis of BI: in four cases BI was associated with neutropenia and in the other four it was associated with the presence of CVC. In the remaining four GVHD was the only risk factor present at the time of diagnosis of BI.
Within the first 30 days from BMT, 18 episodes (38%) were observed: 16 in the presence of neutropenia (viridans streptococci six episodes, Enterococcus sp. three, KESgroup Gram-negative bacteria three, coagulase negative staphylococci, P. aeruginosa, Moraxella sp. and C. albicans one episode each) and two in non-neutropenic patients (both coagulase-negative staphylococci).
The other 18 episodes (38%) were observed after day 100 (six after BMT from related and 12 after BMT from unrelated donors). Four episodes (all BMTs from matchunrelated donors) were observed in the presence of neutropenia (Enterococcus sp. two episodes, S. aureus and P. aeruginosa one episode each). GVHD was present in three episodes, but none of these was CVC-related. The remaining 14 episodes were observed in the absence of neutropenia (coagulase-negative staphylococci six episodes, viridans streptococci two, KES-group Gram-negative bacteria two, Pseudomonas sp., Salmonella sp. and C. parapsilosis one episode each): 12 were diagnosed as CVC-related and in two GVHD was also present, while the remaining two were not associated with neutropenia or CVC; GVHD was present in one case. Gram-negatives 5 1 9 14
Comparison with observations after autologous BMT procedures
These data were compared with those observed in 309 autologous BMT procedures. During a follow-up of 71 399 days (mean 939, 95% CI 680-1198), a total of 82 events were documented, with a rate of 0.11 episodes/100 days at risk.
Following autologous BMT 74 (90%) of the episodes were observed during the neutropenia preceding engraftment, after a mean of 8 days (95% CI 6-11) from transplantation. Gram-positives accounted for 58 episodes (78%), while 11 (15%) were due to Gram-negatives, one (1%) to fungi and four (6%) were mixed/polymicrobial. While there was no statistically significant difference in the distribution of pathogens (P = 0.25), the different incidence of BI during neutropenia between autologous and allogeneic BMT was statistically significant (P Ͻ 0.001). Moreover, the mean time to BI in the presence of neutropenia was shorter after autologous as compared to allogeneic BMT, with a significant statistical difference (P = 0.049).
Only eight (10%) of the episodes were diagnosed in the absence of neutropenia after a mean of 41 days (95% CI 13-69) from transplantation: six (75%) were due to Grampositives and two (25%) to Gram-negatives. The different incidence of BI in the absence of neutropenia among autologous and allogeneic BMT (8/82 vs 26/47) was statistically significant (P Ͻ 0.001), while there was no statistically significant difference in the distributions of pathogens causing BIs (P = 0.62).
In autologous BMT recipients, CVC-related episodes were seven (2% of CVC), and represented 8% of BIs observed in this patient group. Among these episodes, six were due to Gram-positives and one due to Gram-negatives; five CVC-related episodes were diagnosed in the absence of neutropenia. The different incidence of CVCrelated BIs among autologous and allogeneic BMT (7/82 vs 19/47) was statistically significant (P Ͻ 0.001), and there was no statistically significant difference in the pathogens causing CVC-related BIs (P = 0.23). Table 3 summarizes the different clinical situations of patients with BIs according to type of BMT procedure, and etiologies of BI according to the presence of neutropenia or CVC relationship are reported in Tables 1 and 2 .
Septic episodes were judged the main cause of death in seven cases (5%): two following autologous (2%) and five following allogeneic BMT (11%) (P = 0.06). Neutropenia was present in six of them. In two cases the BI was CVCrelated and both cases were due to Candida sp. Other etiologies were Gram-positive bacteria in two episodes, Gramnegative in two and mixed/polymicrobial in one.
Seventy-four episodes (90%) were documented within the first 30 days from BMT, 71 of them in the presence of neutropenia. The difference in incidence of early-onset BI among autologous and allogeneic BMT (74/82 vs 18/47) was statistically significant (P Ͻ 0.001). Moreover, episodes observed in the absence of neutropenia after autologous BMT procedures were diagnosed earlier than in patients receiving allogeneic BMT (41 vs 199 days) (P ϭ 0.001). After day 100 from BMT, only one episode (1%) was documented. The difference in incidence of late- Number in parentheses are 95% confidence interval.
onset BIs among autologous and allogeneic BMT (1/82 vs 18/47) was also statistically significant (P Ͻ 0.001).
Discussion
Bloodstream infections represent an important cause of morbidity in patients undergoing BMT. 3 Many risk factors are associated with this complication in this patient population, but the presence of granulocytopenia, CVC and GVHD represent the leading predisposing conditions. [1] [2] [3] 8 The majority of studies have dealt with early-onset BIs (mainly during pre-engraftment neutropenia) or within the first 100 days from the procedure. 1, 4, 9 We analyzed a cohort of children receiving BMT in order to evaluate etiology and incidence of BIs, with particular attention to time-to-onset, the presence of neutropenia and relationships with CVC, and compared the data with that from a cohort of patients undergoing autologous BMT. The results are worthy of some comments.
Gram-positive bacteria represent the leading cause of BIs in the presence and absence of neutropenia and related to CVCs regardless of type of BMT procedure.
Neutropenia represents the most frequent risk factor associated with BI in BMT patients, and is observed in 74% of episodes. However, it was present in 90% of episodes following autologous and in 45% of episodes following allogeneic BMT (P Ͻ 0.001), and these episodes occurred earlier in patients receiving autologous BMT. We have no clear explanation for this observation. Within the first 30 days, granulocytopenia represented the most important risk factor for the development of bacteremia being present in 96% of episodes observed within this period after autolog-ous BMT and in 89% of episodes observed in this period after allogeneic BMT. However, the overall incidence of early-onset episodes (within 30 days) was 90% in autologous BMT (74/82 documented episodes), while it was only 38% after allogeneic BMT (18/47 documented episode) (P Ͻ 0.001). This may mean that pre-engraftment neutropenia was the most important risk factor for developing BI after autologous BMT, while after allogeneic transplant, other risk factors which became active later, were much more important for determining the risk of this complication.
Another important observation is that almost 1/4 of episodes were observed in the absence of granulocytopenia. This phenomenon was more frequent after allogeneic BMT (55% vs 10%), and this complication developed later during follow-up. CVC-related bacteremias represented the majority of these episodes. However, CVC-related episodes accounted for 40% of episodes in patients receiving allogeneic BMT, but only 8% in patients receiving autologous BMT (P Ͻ 0.001). This particular aspect could be due to the fact that patients undergoing allogeneic BMT use CVC, for a longer period because of the complexity of their management in the post-transplant period (eg for control of GVHD or CMV infection) and are therefore exposed to major risk because of the frequent necessity for venous access, [10] [11] [12] [13] perhaps by parents at home. 13, 14 However, we have no data to support this supposition.
As already mentioned, 55% of episodes occurring after allogeneic BMT were diagnosed in the absence of neutropenia. However, even if the majority (62%) of these episodes were related to the presence of CVC, a non-negligible percentage of them (38%) was not clearly referable to the presence of such a device: in some cases GVHD was present and therefore may have represented an important risk factor, 1,3 but in others, GVHD was not clinically detectable. It is not clear if in these patients GVHD was present (but not clinically detectable) or whether they represent a 'new' risk group. Other well known risk factors were absent (all patients received periodic infusions of immunoglobulins for GVHD prophylaxis or hypogammaglobulinemia and none had evidence of viral infection at the time of diagnosis of BI) or they were not detected (no data regarding the presence of functional asplenia was available). Further studies are needed to clarify this.
Finally, late-onset (after day 100) BIs were virtually absent after autologous BMT (1%), while they represented an important percentage (38%) of episodes diagnosed after allogeneic BMT (P Ͻ 0.001). These episodes were mainly related to neutropenia (due to transplantation failure) and presence of CVC or GVHD, suggesting that the presence of these factors, even a substantial time after transplantation, exposes the patient to risk of severe infection. However, some late-onset episodes were observed even in the absence of risk factors such as neutropenia or clinically detectable GVHD and could not be related to the presence of a CVC. Therefore, the assumption that bacteremia, after day 100 from reinfusion is related to severity of GVHD and intensity of immunosuppressive treatment did not always hold true. [1] [2] [3] In conclusion, while there is no difference in pathogens causing BIs after autologous or allogeneic BMT, patients undergoing the latter procedure have a lower incidence of early-onset (within day 30 from reinfusion) and a higher incidence of late-onset (after day 100 from reinfusion) BIs. Moreover, patients receiving allogeneic BMT have a high incidence of BIs in the absence of neutropenia and even if many of these are related to the presence of CVC or GVHD, a number of episodes occur in the absence of these well known risk factors. Therefore, in our opinion any febrile episode following allogeneic BMT, even in the absence of well known risk factors for infection could signify a severe infection and should therefore be intensively managed.
